Delving into the Latest Updates on 20-valent Pneumococcal Conjugate Vaccine (Suzhou VAC) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine

+ [1]

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Pneumococcal InfectionsPneumonia

Inactive Indication-

Originator Organization

Suzhou VAC

Active Organization

Pfizer Inc.

Suzhou VACSuzhou Ju Microbial Technology Co., Ltd

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

BACKGROUND AND OBJECTIVESThe 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand protection for pneumococcal disease. It contains all 13-valent pneumococcal conjugate vaccine (PCV13) components plus conjugates for 7 additional serotypes. Our primary objective with this study was to evaluate PCV20 tolerability and safety.METHODSIn this phase 3, multi-country, double-blind study, healthy infants born at ≥34 weeks’ gestation were randomly assigned 2:1 to receive PCV20 or PCV13 at 2, 4, 6, and 12 to 15 months of age. Safety assessments included local reactions and systemic events within 7 days after each vaccination, adverse events (AEs) from dose 1 to 1 month after dose 3 and from dose 4 to 1 month after dose 4, and serious AEs and newly diagnosed chronic medical conditions from dose 1 through 6 months after the last dose.RESULTSParticipants received PCV20 (N = 1000) or PCV13 (N = 504); 91.7% received all 4 doses. The frequencies of local reactions and systemic events were generally similar in PCV20 and PCV13 groups, with most reported as mild or moderate. The most common local reaction was injection site pain (PCV20, 24.7% to 40.5%; PCV13, 26.8% to 42.0%); irritability was the most common systemic event (PCV20, 54.8% to 68.2%; PCV13, 54.7% to 68.5%). AE frequencies were similar in both groups. No serious AEs were related to study vaccines. Few newly diagnosed chronic medical conditions were reported (2.8% in both groups). PCV20 was safe across multiple countries, in late preterm infants, and when administered with other vaccines.CONCLUSIONSA 4-dose series of PCV20 had a tolerability and safety profile similar to that of PCV13.

01 Sep 2024·Vaccine

Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea

Article

Author: Byun, Bo-Kyung ; June Choe, Young ; Park, Sun-Kyeong ; Suk, In-Ae ; Lee, Ju-Yeon ; Kang, Dong-Won ; Kim, Hak-Yeon ; Kim, Young-Soo

OBJECTIVESTo evaluate the cost-effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) compared to 13-valent pneumococcal conjugate vaccine (PCV13) for the pediatric population in Korea, where the four-dose vaccine coverage rate is over 97%.METHODSWe constructed a Markov model to calculate the cost and quality-adjusted life-years (QALYs) over 10 years. The health states were susceptible states; disease states, which included invasive pneumococcal diseases such as meningitis, bacteremia, pneumonia, and acute otitis media; and death attributable to pneumococcal disease. The annual incidence and mortality due to pneumococcal diseases were estimated based on the serotypes covered by PCV13 and PCV20, vaccine coverage rate, vaccine effectiveness, and population size. Vaccine, administration, and disease costs were included in the model.RESULTSIn the total population (n = 51,431,305), PCV20 prevented more pneumococcal diseases and deaths, resulting in a gain of 74,855 QALY over PCV13. Meanwhile, the PCV20 group spent $275,136,631 less than the PCV13 group. As PCV20 gained more QALYs but spent less on total medical costs than PCV13, PCV20 was dominant over PCV13.CONCLUSIONSIn the Korean population, PCV20 is a cost-effective and dominant option over PCV13. Our findings provide evidence for decision-making regarding the introduction of PCV20 in countries with high vaccine coverage.

01 Aug 2024·Journal of the American Geriatrics Society

Changes in the cost‐effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults

Article

Author: Schaffner, William ; Nowalk, Mary Patricia ; Harrison, Lee H ; Smith, Kenneth J ; Zimmerman, Richard K ; Wateska, Angela R ; Altawalbeh, Shoroq M ; Lin, Chyongchiou J

AbstractBackgroundMultiple factors, such as less complex U.S. adult pneumococcal recommendations that could increase vaccination rates, childhood pneumococcal vaccination indirect effects that decrease adult vaccination impact, and increased vaccine hesitancy (particularly in underserved minorities), could diminish the cost‐effectiveness of programs to increase pneumococcal vaccination in older adults. Prior analyses supported the economic favorability of these programs.MethodsA Markov model compared no vaccination and current recommendations (either 20‐valent pneumococcal conjugate vaccine [PCV20] alone or 15‐valent pneumococcal conjugate vaccine plus the 23‐valent pneumococcal polysaccharide vaccine [PCV15/PPSV23]) without or with programs to increase vaccine uptake in Black and non‐Black 65‐year‐old cohorts. Pre‐pandemic population‐ and serotype‐specific pneumococcal disease risk and illness/vaccine costs came from U.S. databases. Program costs were $2.19 per vaccine‐eligible person and increased absolute vaccination likelihood by 7.5%. Delphi panel estimates and trial data informed vaccine effectiveness values. Analyses took a healthcare perspective, discounting at 3%/year over a lifetime time horizon.ResultsUptake programs decreased pneumococcal disease overall. In Black cohorts, PCV20 without program cost $216,805 per quality‐adjusted life year (QALY) gained compared with no vaccination; incremental cost‐effectiveness was $245,546/QALY for PCV20 with program and $425,264/QALY for PCV15/PPSV23 with program. In non‐Black cohorts, all strategies cost >$200,000/QALY gained. When considering the potential indirect effects from childhood vaccination, all strategies became less economically attractive. Increased vaccination with less complex strategies had negligible effects. In probabilistic sensitivity analyses, current recommendations with or without programs were unlikely to be favored at thresholds <$200,000/QALY gained.ConclusionCurrent U.S. pneumococcal vaccination recommendations for older adults were unlikely to be economically reasonable with or without programs to increase vaccine uptake. Alternatives to current pneumococcal vaccines that include pneumococcal serotypes associated with adult disease should be considered.

100 Deals associated with 20-valent Pneumococcal Conjugate Vaccine (Suzhou VAC)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pneumococcal Infections	Phase 3	IT	Pfizer Inc.	09 Sep 2020
Pneumococcal Infections	Phase 3	EE	Pfizer Inc.	09 Sep 2020
Pneumococcal Infections	Phase 3	BE	Pfizer Inc.	09 Sep 2020
Pneumococcal Infections	Phase 3	NL	Pfizer Inc.	09 Sep 2020
Pneumococcal Infections	Phase 3	AU	Pfizer Inc.	09 Sep 2020
Pneumococcal Infections	Phase 3	RU	Pfizer Inc.	09 Sep 2020
Pneumococcal Infections	Phase 3	DK	Pfizer Inc.	09 Sep 2020
Pneumococcal Infections	Phase 3	PL	Pfizer Inc.	09 Sep 2020
Pneumococcal Infections	Phase 3	NO	Pfizer Inc.	09 Sep 2020
Pneumococcal Infections	Phase 3	FI	Pfizer Inc.	09 Sep 2020